Meridian Bioscience Stock News

These two overlooked healthcare stocks are underpriced and provide solid, long-term opportunity.

Meridian Bioscience, Innoviva, Horace Mann Educators and Maravai LifeSciences are included in this blog.

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Meridian (VIVO), Innoviva (INVA), Horace (HMN) and Maravai LifeSciences (MRVI) are well poised to gain.

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Meridian (VIVO), Innoviva (INVA), Horace (HMN) and Maravai LifeSciences (MRVI) are well poised to gain.

Photo by 张 嘴 on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Despite COVID-19 and supply-chain issues, the Chinese smartphone market continues to grow. Apple Inc. (NASDAQ: AAPL ), which shipped 50 million new phones in 2021, led the pack, followed closely by Meridian Bioscience Inc. ’s (NASDAQ: VIVO ) Vivo Mobile . According to a study by McGill University in Montreal, Quebec, China continues to have the most smartphones in the world with more than 900 million users. With cell phones continuing to be part of daily life in China, which has the most access to 5G in the world, companies like FingerMotion Inc. (Nasdaq: FNGR ) and its mobile payment and recharge platforms continue to be a growing solution provider for the nation’s users. FingerMotion recently announced its shares of common stock are listed and available for trading on the Nasdaq Capital Market under the ticker symbol FNGR. “Listing on Nasdaq provides us greater exposure within the investment community as we execute on our ambitious growth strategies and key upcoming milestones, including expansion into …

Meridian Bioscience Inc. (NASDAQ:VIVO) has a beta value of 0.42 and has seen 0.51 million shares traded in the last trading session. The company, currently valued at $1.08B, closed the last trade at $24.74 per share which meant it lost -$0.46 on the day or -1.83% during that session. The VIVO stock price is -20.21% Meridian Bioscience Inc. Is A Buy Small Cap Stock: Analysts Read More »

We identified 18 stocks in S&P 500 with strong momentum based on our criteria. Ten of the stocks we identified made new all-time highs.

Impactive recently disclosed a stake in the life science company. The activist fund has built a reputation for its approach toward ESG investing.

Meridian Bioscience Inc. (VIVO) shares closed this week 24.4% higher than it did at the end of last week. The stock is currently up 30.4% year-to-date, down 3.1% over the past 12 months, and up 117.1% over the past five years. This week, the Dow Jones Industrial Average rose 0.4%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $27.23 and as low as $21.50 this week.Trading volume this week was 14.8% lower than the 10-day average and 9.0% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -571.2% The company's stock price performance over the past 12 months beats the peer average by -52.3% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 31.6% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Meridian Bioscience (VIVO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Meridian Bioscience (VIVO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Meridian Bioscience <> rose following its Q1 results and a raised fiscal 2022 guidance.The company said net revenues in Q1 fiscal were $88.3M, only 5% below the record $92.9M in